![Brandon Hants](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Brandon Hants
Nessuna posizione attualmente
Patrimonio netto: 570 $ in data 30/11/2023
Profilo
Brandon Hants served as the Chief Financial Officer at Singulex, Inc. from 2018 to 2019, and at Applied Molecular Transport, Inc. from 2022 to 2023.
He received an undergraduate degree from the University of California, Santa Barbara, and an MBA from the University of San Francisco.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
27/12/2023 | 2 921 ( 0.01% ) | 570 $ | 30/11/2023 |
Precedenti posizioni note di Brandon Hants
Società | Posizione | Fine |
---|---|---|
APPLIED MOLECULAR TRANSPORT INC. | Direttore Finanziario/CFO | 27/12/2023 |
Singulex, Inc.
![]() Singulex, Inc. Miscellaneous Commercial ServicesCommercial Services Singulex, Inc. provides biotechnological research and development services. It also provides instrumentation and immunoassays with the requisite sensitivity and specificity to enable biomarker discovery and validation for drug safety and efficacy. The company was founded by Robert S. Puskas in November 1997 and is headquartered in Alameda, CA. | Direttore Finanziario/CFO | 01/01/2019 |
Formazione di Brandon Hants
University of San Francisco | Masters Business Admin |
University of California, Santa Barbara | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
APPLIED MOLECULAR TRANSPORT INC. | Health Technology |
Aziende private | 1 |
---|---|
Singulex, Inc.
![]() Singulex, Inc. Miscellaneous Commercial ServicesCommercial Services Singulex, Inc. provides biotechnological research and development services. It also provides instrumentation and immunoassays with the requisite sensitivity and specificity to enable biomarker discovery and validation for drug safety and efficacy. The company was founded by Robert S. Puskas in November 1997 and is headquartered in Alameda, CA. | Commercial Services |
- Borsa valori
- Insiders
- Brandon Hants